Cytosorbents (CTSO) Cash from Operations Growth (3y) (2013 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 27.41% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 16.81% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 27.02% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 22.38% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 30.85% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 168.71% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 16.21% |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 12.26% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 9.30% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | 56.19% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.19% |
| Mar 31, 2026 | 27.96% |
| Dec 31, 2025 | 3.33% |
| Sep 30, 2025 | 27.40% |
| Jun 30, 2025 | 42.75% |
| Mar 31, 2025 | 24.70% |
| Dec 31, 2024 | 24.74% |
| Sep 30, 2024 | 15.85% |
| Jun 30, 2024 | -33.03% |
| Mar 31, 2024 | -27.25% |
| Dec 31, 2023 | -82.29% |
| Sep 30, 2023 | -16.60% |
| Jun 30, 2023 | -77.34% |
| Mar 31, 2023 | 1.06% |
| Dec 31, 2022 | -9.00% |
| Sep 30, 2022 | -8.95% |
| Jun 30, 2022 | -36.11% |
| Mar 31, 2022 | -24.20% |
| Dec 31, 2021 | -26.59% |
| Sep 30, 2021 | -16.18% |